within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ09_Danicopan;

model Danicopan
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 1.6666666666666667e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.06,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008333333333333333,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Danicopan</td></tr><tr><td>ATC code:</td><td>L04AJ09</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>60</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Danicopan is an orally administered, selective oral factor D inhibitor developed as a complement pathway inhibitor, primarily for use in paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated disorders. It is not approved by the FDA or EMA as of 2024 but has been investigated in clinical trials for PNH, including as add-on therapy to C5 inhibitors for patients with extravascular hemolysis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated based on phase I and II clinical trial publications and limited publicly available data regarding healthy adult subjects after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AJ09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Danicopan;
